Recent trials involving human participants of potential disease-modifying therapies for DM1, including antisense oligonucleotide and the GSK3β inhibitor tideglusib, emphasize clinical trial readiness as a major priority for the DM1 research community (39). This evidence concerns the gene GSK3B and myotonic dystrophy type 1.